肝癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT04157985 / NCI-2020-02016

Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

AI 简述这是一项III期试验，比较免疫治疗不同治疗时长用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 3

NCI NCT06265285 / NCI-2024-00637

Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

AI 简述这是一项III期试验，比较Nivolumab在家与在诊所给药用于多种癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 3

NCI NCT07166406 / NCI-2025-05951

Testing Immunotherapy with or without Stereotactic Body Radiation Therapy in Patients with Advanced Liver Cancer, HELIO-RT Trial

AI 简述这是一项III期试验，在United States、Canada开展，研究免疫治疗联合或不联合立体定向放疗用于晚期肝癌。

?

适用疾病: Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer；Advanced Hepatocellular Carcinoma
干预: 未列出
地点: United States，Canada
申办方: NRG Oncology

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT03895359

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

AI 简述这是一项III期试验，比较TACE联合立体定向放疗与单纯TACE用于肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Stereotactic Body Radiation，Transarterial Chemoembolization
地点: Canada
申办方: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov NCT04803994

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

AI 简述这是一项III期试验，比较Atezolizumab联合Bevacizumab与TACE用于中期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Atezolizumab，Bevacizumab，TACE
地点: Austria，France，Germany，Italy 等 2 个
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 3 手术/操作

ClinicalTrials.gov NCT04868149

Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS

AI 简述这是一项III期试验，比较腹腔镜与开腹ALPPS手术用于肝癌。

?

适用疾病: Liver Cancer
干预: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)
地点: Hong Kong
申办方: The University of Hong Kong

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

AI 简述这是一项III期试验，比较标准免疫治疗与每3个月给药一次的方案用于多种癌症。

?

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05201404 / NCI-2023-08219

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

AI 简述这是一项III期试验，研究Namodenoson对比安慰剂用于Child-Pugh B7级肝硬化晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Cirrhosis
干预: Namodenoson，Placebo
地点: United States，Bosnia and Herzegovina，Bulgaria，Israel 等 5 个
申办方: Can-Fite BioPharma

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT05317819

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

AI 简述这是一项3期试验，在台湾和越南研究ADI-PEG20用于高精氨酸水平和不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Advanced Hepatocellular Carcinoma
干预: ADI-PEG20，Placebo
地点: Taiwan，Vietnam
申办方: Polaris Group

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05482516 / NCI-2023-01487

Evaluating Novel Therapies in ctDNA Positive GI Cancers

AI 简述这是一项3期试验，评估Atezolizumab联合贝伐珠单抗用于ctDNA阳性胃肠癌，包括结肠、直肠、胃癌等，在美国开展。

?

适用疾病: Colon Adenocarcinoma；Rectal Adenocarcinoma；Gastric Adenocarcinoma
干预: Atezolizumab，Bevacizumab
地点: United States
申办方: Georgetown University

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06007846

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

AI 简述这是一项II/III期试验，研究美金刚用于肝硬化合并肝癌患者。

?

适用疾病: Hepatocellular Carcinoma；Cirrhosis
干预: Namenda
地点: United States
申办方: Inova Health Care Services

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT06109272 / NCI-2024-00270

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

AI 简述这是一项II/III期试验，研究Livmoniplimab联合Budigalimab用于肝细胞癌。在美国、法国等地开展。

?

适用疾病: Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: Livmoniplimab，Budigalimab，Durvalumab，Atezolizumab
地点: United States，France，Italy，Puerto Rico 等 2 个
申办方: AbbVie

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06904170

Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

AI 简述这是一项II/III期试验，研究度伐利尤单抗和替西木单抗联合或不联合HAIC用于肝细胞癌，在法国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Durvalumab Plus Tremelimumab，HAIC (GEMOX)
地点: France
申办方: UNICANCER

正在招募 Phase 2, Phase 3 药物手术/操作放疗

ClinicalTrials.gov NCT07293468

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

AI 简述这是一项II/III期试验，在香港比较SBRT与SIRT联合免疫治疗用于不可切除的肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Transarterial chemoembolization (TACE)，Stereotactic Body Radiation Therapy (SBRT)，SIRT Yttrium-90，Atezolizumab & Bevacizumab
地点: Hong Kong
申办方: Tuen Mun Hospital

正在招募 Phase 2, Phase 3 联合产品

ClinicalTrials.gov NCT07302919

Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

AI 简述这是一项II/III期试验，比较DEB-DoxNic-TACE与标准TACE用于肝细胞癌。在瑞士开展。

?

适用疾病: Hepato Cellular Carcinoma (HCC)
干预: DEB-DoxNic-TACE，current standard of care
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

正在招募 Phase 4

NCI NCT02081755 / NCI-2017-02502

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

AI 简述这是一项4期试验，研究依维莫司用于肝癌肝移植后的治疗。

?

适用疾病: Hepatocellular Carcinoma
干预: 未列出
地点: United States
申办方: Baylor University Medical Center

正在招募 Phase 2

NCI NCT01174121 / NCI-2019-00142

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合Pembrolizumab用于转移性癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT04524871 / NCI-2020-07043

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

AI 简述这是一项1/2期试验，研究多种免疫治疗组合用于晚期肝癌。

?

适用疾病: Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer；Metastatic Hepatocellular Carcinoma
干预: 未列出
地点: United States
申办方: Hoffmann-La Roche

正在招募 Phase 1, Phase 2

NCI NCT04787042 / NCI-2021-09248

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

AI 简述这是一项I/II期试验，研究ST-067用于实体瘤、黑色素瘤、肾细胞癌和三阴性乳腺癌，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Metastatic Urothelial Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Simcha IL-18, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05584670 / NCI-2023-00867

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，首次人体研究SAR445877用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sanofi Aventis

正在招募 Phase 2

NCI NCT05969860 / NCI-2023-05420

At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls

AI 简述这是一项II期试验，比较在家与在医院进行癌症治疗用于晚期癌症患者。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Head and Neck Cancer；Advanced Melanoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 1, Phase 2

NCI NCT05914116 / NCI-2024-01206

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/IIa期试验，在美国研究DB-1311/BNT324用于晚期/转移性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06596694 / NCI-2025-00174

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

AI 简述这是一项I/II期试验，研究Patritumab Deruxtecan用于胃肠道癌症，在美国开展。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06725758 / NCI-2025-08359

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

AI 简述这是一项I/II期试验，在美国开展，研究ODM-212用于晚期实体瘤。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Orion Corporation, Orion Pharma

正在招募 Phase 1, Phase 2

NCI NCT07335497 / NCI-2026-03444

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究CR-001用于局部晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Crescent Biopharma, Inc.

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT02174549 / NCI-2015-01627

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

AI 简述这是一项I/II期试验，确定Tirapazamine联合栓塞治疗肝癌的剂量，在美国开展。

?

适用疾病: Hepatocellular Carcinoma；Gastrointestinal Cancer Metastatic；Neuroendocrine Tumors
干预: Tirapazamine，Conventional Transarterial Embolization (TAE)
地点: United States
申办方: Teclison Ltd.

正在招募 Phase 2 联合产品药物

ClinicalTrials.gov / NCI NCT03259867 / NCI-2017-01862

Combination of TATE and PD-1 Inhibitor in Liver Cancer

AI 简述这是一项II期试验，研究Nivolumab联合肝动脉栓塞用于肝癌和胃癌。

?

适用疾病: Hepatocellular Carcinoma；Gastric Cancer；BCLC Stage C Hepatocellular Cancer
干预: Nivolumab Injectable Product，Trans-arterial tirapazamine embolization
地点: United States
申办方: Teclison Ltd.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03539822 / NCI-2019-00380

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

AI 简述这是一项I/II期试验，研究Cabozantinib联合Durvalumab加或不加Tremelimumab用于胃癌、食管腺癌等消化道肿瘤。

?

适用疾病: Gastric Cancer；Esophageal Adenocarcinoma；Hepatocellular Carcinoma
干预: Cabozantinib，Durvalumab，Tremelimumab
地点: United States
申办方: Anwaar Saeed

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT03812874

A Study of PTX-9908 Injection for Non-resectable HCC with TACE

AI 简述这是一项I/II期试验，研究PTX-9908注射液联合TACE用于不可切除的肝细胞癌。在台湾开展。

?

适用疾病: Carcinoma, Hepatocellular
干预: PTX-9908 Injection，Placebo
地点: Taiwan
申办方: TCM Biotech International Corp.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03897543 / NCI-2020-07077

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

AI 简述这是一项I/II期试验，研究ABX196联合Nivolumab用于肝细胞癌。

?

适用疾病: Carcinoma, Hepatocellular；Hepatocellular Carcinoma
干预: ABX196
地点: United States
申办方: Abivax S.A.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03899428

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

AI 简述这是一项II期试验，研究免疫检查点治疗对比靶向治疗用于HBsAg阳性晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Durvalumab，Sorafenib，Lenvatinib，Regorafenib
地点: Hong Kong
申办方: Humanity & Health Medical Group Limited

正在招募 Phase 1, Phase 2 生物制剂手术/操作放疗

ClinicalTrials.gov / NCI NCT03942328 / NCI-2019-02452

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

AI 简述这是一项I/II期试验，研究自体树突状细胞联合Atezolizumab和贝伐珠单抗用于不可切除肝癌，在美国开展。

?

适用疾病: Stage III Hepatocellular Carcinoma AJCC v8；Stage III Intrahepatic Cholangiocarcinoma AJCC v8；Stage IV Hepatocellular Carcinoma AJCC v8
干预: Atezolizumab，Bevacizumab，External Beam Radiation Therapy，Pheresis
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04114136 / NCI-2020-11521

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

AI 简述这是一项II期试验，研究PD-1抑制剂联合二甲双胍、罗格列酮用于多种实体瘤。

?

适用疾病: Melanoma；NSCLC；Hepatocellular Carcinoma
干预: Nivolumab or Pembrolizumab (dependent upon approved indication)，Metformin，Rosiglitazone
地点: United States
申办方: Dan Zandberg

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04134559 / NCI-2019-08025

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Pembrolizumab用于儿童肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma, Childhood；Fibrolamellar Carcinoma；Liver Cancer
干预: Pembrolizumab
地点: United States
申办方: Allison O'Neill, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04204850

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

AI 简述这是一项II期试验，研究卡博替尼用于肝移植后复发性肝细胞癌，在加拿大开展。

?

适用疾病: Hepatocellular Carcinoma；Recurrent Cancer；Liver Transplant
干预: Cabozantinib
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04380545 / NCI-2020-02614

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

AI 简述这是一项I/II期试验，研究纳武利尤单抗、氟尿嘧啶和干扰素α-2b用于不可切除的纤维板层癌。

?

适用疾病: Stage III Hepatocellular Carcinoma AJCC v8；Stage IIIA Hepatocellular Carcinoma AJCC v8；Stage IIIB Hepatocellular Carcinoma AJCC v8
干预: Fluorouracil，Nivolumab，Recombinant Interferon Alpha 2b-like Protein
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂放疗

ClinicalTrials.gov / NCI NCT04430452 / NCI-2020-03671

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Durvalumab联合或不联合Tremelimumab用于晚期肝细胞癌。

?

适用疾病: Advanced Hepatocellular Carcinoma；Stage III Hepatocellular Carcinoma AJCC v8；Stage IIIA Hepatocellular Carcinoma AJCC v8
干预: Durvalumab，Hypofractionated Radiation Therapy，Tremelimumab
地点: United States
申办方: Mary Feng, MD

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT04472767

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究卡博替尼联合伊匹单抗/纳武单抗和TACE用于肝细胞癌，在美国开展。

?

适用疾病: Hepatocellular Carcinoma；HCC
干预: Nivolumab，Ipilimumab，Cabozantinib，Transarterial Chemoembolization
地点: United States
申办方: University of California, Irvine

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04634357 / NCI-2022-06445

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

AI 简述这是一项I/II期试验，研究ET140203 T细胞用于儿童肝母细胞瘤或肝细胞癌，在美国开展。

?

适用疾病: Hepatoblastoma；Hepatocellular Carcinoma (HCC)；Liver Neoplasms
干预: ET140203 T Cells
地点: United States
申办方: Eureka Therapeutics Inc.

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04851119 / NCI-2021-02852

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

AI 简述这是一项I/II期试验，研究Tegavivint用于复发或难治性实体瘤，包括淋巴瘤和硬纤维瘤。

?

适用疾病: Colorectal Carcinoma；Endometrial Carcinoma；Melanoma
干预: Biospecimen Collection，Dual X-ray Absorptiometry，Tegavivint，X-Ray Imaging
地点: United States
申办方: Children's Oncology Group

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT04864054 / NCI-2021-12314

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

AI 简述这是一项I/II期试验，研究GPC3靶向T细胞疗法ECT204用于晚期肝细胞癌，在美国、台湾开展。

?

适用疾病: Hepatocellular Carcinoma；Liver Cancer, Adult；Liver Neoplasm
干预: ECT204 T cells
地点: United States，Taiwan
申办方: Eureka Therapeutics Inc.

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT04912765

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

AI 简述这是一项II期试验，研究新抗原树突状细胞疫苗联合Nivolumab用于肝细胞癌和结直肠癌肝转移，在新加坡开展。

?

适用疾病: Hepatocellular Carcinoma；Hepatocellular Cancer；Colorectal Cancer
干预: Neoantigen Dendritic Cell Vaccine，Nivolumab
地点: Singapore
申办方: National Cancer Centre, Singapore

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT04988945

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究TACE和SBRT后双免疫治疗用于肝细胞癌降期治疗。

?

适用疾病: HCC
干预: TACE，SBRT，Durvalumab，Tremelimumab
地点: Hong Kong
申办方: The University of Hong Kong

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT05168163

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

AI 简述这是一项II期试验，研究Atezolizumab联合Cabozantinib或Lenvatinib用于不可切除或转移性肝癌，在美国开展。

?

适用疾病: Locally Advanced Hepatocellular Carcinoma；Metastatic Hepatocellular Carcinoma；Stage III Hepatocellular Carcinoma AJCC v8
干预: Atezolizumab，Cabozantinib，Lenvatinib
地点: United States
申办方: Academic and Community Cancer Research United

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05185505

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

AI 简述这是一项IV期试验，研究Atezolizumab和Bevacizumab在肝移植前用于超米兰标准的肝细胞癌。在美国开展。

?

适用疾病: Hepatocellular Carcinoma；Hepatocellular Cancer
干预: Atezolizumab，Bevacizumab
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05185739

Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

AI 简述这是一项II期试验，研究围手术期Pembrolizumab和Lenvatinib用于可切除的肝细胞癌。在英国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Pembrolizumab，Lenvatinib，Pembrolizumab and Lenvatinib
地点: United Kingdom
申办方: University College, London

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05223816 / NCI-2023-09540

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

AI 简述这是一项II期试验，在美国研究VG161单药或联合纳武利尤单抗用于肝细胞癌或肝内胆管癌。

?

适用疾病: Hepatocellular Carcinoma；Intrahepatic Cholangiocarcinoma；Stage III Hepatocellular Cancer
干预: VG161，Nivolumab Injection [Opdivo]
地点: United States
申办方: Virogin Biotech Canada Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05257590

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究CVM-1118联合Nivolumab用于不可切除晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Advanced Cancer
干预: Nivolumab Injection [Opdivo]，CVM-1118
地点: Taiwan
申办方: TaiRx, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05269381 / NCI-2022-01258

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究新抗原肽疫苗联合Pembrolizumab用于晚期实体瘤。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Anatomic Stage IIIB Breast Cancer AJCC v8
干预: Cyclophosphamide，Neoantigen Peptide Vaccine，Pembrolizumab，Sargramostim
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT05304481

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

AI 简述这是一项2期试验，研究活化T淋巴细胞（ATL）用于肝细胞癌。在台湾开展。

?

适用疾病: Hepatocellular Carcinoma
干预: ATL administration
地点: Taiwan
申办方: Lukas Biomedical Inc.

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05331911

Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors

AI 简述这是一项4期试验，比较丙泊酚全静脉麻醉与七氟烷麻醉用于肝癌切除术，在台湾开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Propofol，Sevoflurane
地点: Taiwan
申办方: Kaohsiung Medical University Chung-Ho Memorial Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05366829 / NCI-2022-05056

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Tislelizumab用于肝定向治疗后的肝细胞癌，在美国开展。

?

适用疾病: Carcinoma, Hepatocellular；Liver Cell Carcinoma；BCLC Stage A Hepatocellular Cancer
干预: Tislelizumab
地点: United States
申办方: Rutgers, The State University of New Jersey

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05417932 / NCI-2024-05383

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

AI 简述这是一项1/2期试验，研究SCG101用于乙型肝炎病毒相关肝细胞癌。

?

适用疾病: Hepatitis B Virus Related Hepatocellular Carcinoma；Hepatocellular Carcinoma Recurrent；Hepatitis Virus-Related Hepatocellular Cancer
干预: SCG101
地点: United States，Hong Kong，Singapore
申办方: SCG Cell Therapy Pte. Ltd.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05440708 / NCI-2022-09242

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

AI 简述这是一项1/2期试验，在United States开展，研究TTI-101单药或联合治疗用于不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: TTI-101，Pembrolizumab，Atezolizumab，Bevacizumab
地点: United States
申办方: Tvardi Therapeutics, Incorporated

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05440864

Durvalumab and Tremelimumab in Resectable HCC

AI 简述这是一项2期试验，在Canada, Italy, Spain等地开展，研究度伐利尤单抗联合Tremelimumab用于可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Tremelimumab
地点: Canada，Italy，Spain
申办方: University Health Network, Toronto

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT05451043

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

AI 简述这是一项II期试验，研究Durvalumab和Tremelimumab联合普萘洛尔及化疗用于晚期肝胆肿瘤。

?

适用疾病: Pancreatic Cancer；Hepatocellular Cancer；Biliary Tract Cancer
干预: Durvalumab，Gemcitabine，Nab paclitaxel，Tremelimumab
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05468359 / NCI-2022-06602

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

AI 简述这是一项I/II期试验，研究环磷酰胺、索拉非尼、贝伐珠单抗和阿替利珠单抗用于儿童实体瘤。

?

适用疾病: Refractory Solid Tumor；Hepatocellular Carcinoma；Malignant Solid Tumor
干预: Atezolizumab，Sorafenib，Bevacizumab，Cyclophosphamide
地点: United States
申办方: St. Jude Children's Research Hospital

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05516628

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

AI 简述这是一项II期试验，通过多组学预测阿替利珠单抗联合贝伐珠单抗辅助治疗肝细胞癌的应答与复发，在新加坡开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Surgical Resection，Adjuvant Atezolizumab-Bevacizumab Therapy
地点: Singapore
申办方: National Cancer Centre, Singapore

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05528952

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究UCPVax联合阿替利珠单抗和贝伐珠单抗用于不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Atezolizumab，Bevacizumab，UCPVax
地点: France
申办方: Centre Hospitalier Universitaire de Besancon

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05620771 / NCI-2022-09476

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

AI 简述这是一项II期试验，研究Y90联合Atezolizumab+Bevacizumab或TKI用于高风险肝细胞癌，在美国开展。

?

适用疾病: Hepatocellular Carcinoma；Stage IV Hepatocellular Cancer；Advanced Hepatocellular Carcinoma
干预: Y90 + Atezolizumab and Bevacizumab，Y90 + TKI
地点: United States
申办方: Northwestern University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05669339 / NCI-2024-06019

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Irinotecan、Sonidegib、Sorafenib用于晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: Irinotecan，Sonidegib，Sorafenib
地点: United States
申办方: University of Florida

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05690048

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

AI 简述这是一项II期试验，研究粪便微生物移植用于克服肝细胞癌对Atezolizumab/Bevacizumab的耐药，在德国开展。

?

适用疾病: Immunotherapy；HCC - Hepatocellular Carcinoma
干预: Fecal microbiota transfer，Vancomycin Oral Capsule，Atezolizumab + Bevacizumab，Placebo Vancomycin Oral Capsule
地点: Germany
申办方: Michael Dill

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05733598 / NCI-2023-06043

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

AI 简述这是一项2期试验，研究RP2联合二线治疗用于局部晚期或转移性肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Biliary Tract Cancer；Stage III Hepatocellular Cancer
干预: RP2，Bevacizumab，Atezolizumab，Durvalumab
地点: United States
申办方: Replimune, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05797805 / NCI-2023-04439

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

AI 简述这是一项I/II期试验，研究Tegavivint联合其他药物用于晚期肝细胞癌。

?

适用疾病: Advanced Hepatocellular Carcinoma；BCLC Stage B Hepatocellular Cancer；BCLC Stage C Hepatocellular Cancer
干预: Tegavivint，Lenvatinib，Cabozantinib
地点: United States，Canada
申办方: Iterion Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

AI 简述这是一项I/II期试验，研究GI-102单药或联合其他药物用于晚期实体瘤。在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Soft Tissue Sarcoma (STS)
干预: GI-102 subcutaneous (SC)，GI-102，doxorubicin，paclitaxel
地点: United States，South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05842174

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

AI 简述这是一项I/II期试验，在美国开展，研究羟氯喹联合碘油用于肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Hydroxychloroquine，Lipiodol，Placebo
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT05844046

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

AI 简述这是一项II期试验，在德国开展，研究Durvalumab联合Tremelimumab和贝伐珠单抗用于不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: durvalumab, tremelimumab, bevacizumab
地点: Germany
申办方: Enrico De Toni

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05901519

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究泼尼松保护肝脏用于接受立体定向放射治疗的肝细胞癌患者，在美国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Prednisone
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05919264 / NCI-2023-06767

FOG-001 in Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚开展，研究FOG-001联合化疗或免疫治疗用于局部晚期或转移性实体瘤。

?

适用疾病: Cancer；Colorectal Cancer；Solid Tumor
干预: FOG-001，mFOLFOX-6，Nivolumab，Trifluridine/tipiracil
地点: United States，Australia
申办方: Parabilis Medicines, Inc.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05992220

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

AI 简述这是一项II期试验，研究Atezolizumab联合贝伐珠单抗加或不加放疗用于大血管侵犯的肝细胞癌，在韩国开展。

?

适用疾病: Hepatocellular Carcinoma；Hepatocellular Cancer；Hepatocellular Carcinoma Non-resectable
干预: Atezolizumab plus bevacizumab, combined EBRT to vascular invasion，Atezolizumab plus bevacizumab
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06027086 / NCI-2025-00005

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

AI 简述这是一项I/II期试验，研究DRP-104联合Durvalumab用于晚期纤维板层癌。

?

适用疾病: Fibrolamellar Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: Durvalumab，DRP-104
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06034977

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究ADI-PEG 20联合Lenvatinib用于不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: ADI-PEG20
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06096779 / NCI-2024-00205

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

AI 简述这是一项II期试验，研究Atezolizumab联合或不联合Bevacizumab用于不可切除肝细胞癌且Child-pugh B7和B8肝硬化。

?

适用疾病: Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: Atezolizumab，Bevacizumab
地点: United States，Puerto Rico
申办方: Genentech, Inc.

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT06114082

TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma

AI 简述这是一项II期试验，比较TACE使用伊达比星与多柔比星化疗栓塞用于肝细胞癌。在韩国开展。

?

适用疾病: Hepatocellular Carcinoma；Liver Cancer
干预: IDA-TACE，DOX-TACE
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06133062

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Atezolizumab和Bevacizumab联合质子放疗用于不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma Non-resectable
干预: Atezolizumab，Bevacizumab，Proton radiotherapy
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT06166576

Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis

AI 简述这是一项II期试验，研究消融性放射栓塞用于伴有门静脉癌栓的肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Ablative radioembolization
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT06178198

Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究放射肝切除（钇-90树脂微球）用于大单发肝细胞癌。在韩国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Ablative radioembolization using Yttrium-90 resin microspheres
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究MDX2001用于晚期实体瘤，包括胆管癌、乳腺癌等。

?

适用疾病: Biliary Tract Cancer；Breast Cancer；Cervical Cancer
干预: MDX2001
地点: United States
申办方: ModeX Therapeutics, An OPKO Health Company

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06254248

Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Atezolizumab-Bevacizumab用于肝移植后复发性肝细胞癌，在法国开展。

?

适用疾病: Liver Transplant；Hepatocellular Carcinoma Recurrent；Systemic Treatment
干预: Systemic therapy
地点: France
申办方: Assistance Publique - Hôpitaux de Paris

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06294548 / NCI-2025-07476

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

AI 简述这是一项I/II期试验，研究Valemetostat联合阿替利珠单抗和贝伐珠单抗用于肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: Valemetostat，Atezolizumab，Bevacizumab
地点: United States
申办方: University of Alabama at Birmingham

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06339424

Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究阿替利珠单抗和贝伐珠单抗联合光子放疗用于不可切除肝细胞癌，在台湾等地开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Atezolizumab，Bevacizumab，Photon radiotherapy
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06362369 / NCI-2024-03436

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

AI 简述这是一项I/II期试验，研究Alintegimod联合Ipilimumab及Nivolumab用于晚期实体瘤。

?

适用疾病: Advanced Cancer；Advanced Solid Tumor；Melanoma
干预: Alintegimod，Ipilimumab，Nivolumab
地点: United States
申办方: 7 Hills Pharma, LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

AI 简述这是一项II期试验，研究减少免疫检查点抑制剂给药频率用于晚期癌症。在新加坡开展。

?

适用疾病: Carcinoma, Hepatocellular；Gastric Adenocarcinoma；GastroEsophageal Cancer
干预: Extended Dosing Interval - A，Extended Dosing Interval - B，Extended Dosing Interval - C，Standard of Care - A
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06518434

A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients

AI 简述这是一项II期试验，研究医用大麻油用于不可治疗的肝癌患者。

?

适用疾病: Hepatocellular Carcinoma；Cannabis
干预: Medical Cannabis
地点: Netherlands
申办方: University Medical Center Groningen

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06526104 / NCI-2024-09706

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

AI 简述这是一项II期试验，在美国开展，研究Tremelimumab和Durvalumab联合用于伴有Child-Pugh B级肝硬化的晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Cirrhosis, Liver；BCLC Stage B Hepatocellular Cancer
干预: Tremelimumab，Durvalumab
地点: United States
申办方: The University of Texas Health Science Center at San Antonio

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT06526338

Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

AI 简述这是一项II期试验，在美国开展，研究IP-001辅助治疗用于手术切除联合消融或单独消融后的肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: 1.0% IP-001 for injection，Surgical Resection and Local Ablation，Local Ablation Alone
地点: United States
申办方: Robert C. Martin

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06527495

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

AI 简述这是一项I/II期试验，在埃及开展，研究索拉非尼的药物基因组学用于肝细胞癌。

?

适用疾病: HCC；Hepatocellular Carcinoma
干预: Sorafenib
地点: Egypt
申办方: Assiut University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06551272

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究肠道微生物调节EXL01用于肝细胞癌，在法国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: EXL01
地点: France
申办方: Center Eugene Marquis

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06553885 / NCI-2024-09177

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

AI 简述这是一项II期试验，在美国开展，研究Enfortumab Vedotin用于晚期或转移性结直肠癌或肝细胞癌。

?

适用疾病: Metastatic Colorectal Cancer；Hepatocellular Carcinoma；Stage III Colorectal (Colon or Rectal) Cancer
干预: Enfortumab Vedotin
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 4 药物手术/操作

ClinicalTrials.gov NCT06594744

Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC

AI 简述这是一项IV期试验，比较内镜下食管静脉曲张结扎术与卡维地洛用于预防肝癌患者首次食管静脉曲张出血，在台湾开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Esophageal Varices
干预: Endoscopic variceal ligation，Carvedilol
地点: Taiwan
申办方: Taipei Veterans General Hospital, Taiwan

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT06632717

Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究肝动脉灌注化疗联合碘油栓塞用于晚期肝细胞癌，在台湾开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Cisplatin，5-fluorouracil，Lipiodol embolization
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06695026

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

AI 简述这是一项1/2期试验，研究RZ-001联合缬更昔洛韦和阿替利珠单抗/贝伐珠单抗用于肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: RZ-001 Dose 1，RZ-001 Dose 2，RZ-001 Dose 3
地点: South Korea
申办方: Rznomics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06698250 / NCI-2025-00874

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

AI 简述这是一项2期试验，研究Zanzalintinib联合Durvalumab和Tremelimumab用于不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: Zanzalintinib，Durvalumab，Tremelimumab
地点: United States
申办方: Anwaar Saeed

正在招募 Phase 4 手术/操作

ClinicalTrials.gov NCT06717919

HOPE Against Cancer Recurrence in HCC

AI 简述这是一项IV期试验，研究低温氧合灌注对比传统冷保存用于肝移植中的肝癌。

?

适用疾病: Liver Transplantation；HCC；Oncological Outcomes
干预: Hypothermic oxygenated perfusion，Conventional cold storage
地点: United States，Austria，Belgium，Czechia 等 13 个
申办方: Philipp Dutkowski

正在招募 Phase 1, Phase 2 生物制剂药物放疗

ClinicalTrials.gov NCT06725121

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

AI 简述这是一项I/II期试验，在加拿大开展，研究放疗联合免疫治疗用于晚期肝癌肝移植前降期治疗。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Macrovascular Invasion；Liver Transplant Surgery
干预: Atezolizumab & Bevacizumab，Yttrium-90 (Y-90)，Stereotactic body radiotherapy (SBRT)
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT06726161 / NCI-2025-03112

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

AI 简述这是一项I/II期试验，研究RYZ811和RYZ801用于GPC3阳性不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)；BCLC Stage B Hepatocellular Cancer；BCLC Stage C Hepatocellular Cancer
干预: RYZ811，RYZ801
地点: United States
申办方: RayzeBio, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06789757

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

AI 简述这是一项II期试验，研究Atezolizumab、Bevacizumab和Memantine用于肝细胞癌。在美国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Memantine Hydrochloride，Bevacizumab，Atezolizumab
地点: United States
申办方: Inova Health Care Services

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06789848 / NCI-2025-01329

Ligufalimab and Cadonilimab in Advanced Liver Cancers

AI 简述这是一项II期试验，研究Ligufalimab和Cadonilimab用于晚期肝癌和胆道癌。在美国开展。

?

适用疾病: Advanced Hepatocellular Carcinoma；Refractory Hepatocellular Carcinoma；Biliary Tract Cancer
干预: Ligufalimab，Cadonilimab
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06811116 / NCI-2025-00837

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

AI 简述这是一项I/II期试验，在美国开展，研究Sapanisertib联合Cabozantinib用于转移性肝癌伴β-catenin基因改变。

?

适用疾病: Advanced Hepatocellular Carcinoma；Metastatic Hepatocellular Carcinoma；Stage III Hepatocellular Carcinoma AJCC v8
干预: Biospecimen Collection，Cabozantinib S-malate，Imaging Procedure，Sapanisertib
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT06819566

Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC

AI 简述这是一项II期试验，在韩国开展，研究内镜下食管静脉曲张套扎术用于接受Atezo/Bev治疗的肝细胞癌伴高危食管静脉曲张患者。

?

适用疾病: Hepatocellular Carcinoma；Esophageal Varix；Bleeding Esophageal Varices
干预: Endoscopic variceal ligation (EVL)
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT06828380

A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion

AI 简述这是一项II期试验，研究免疫治疗联合放疗对比单用免疫治疗用于伴血管侵犯的肝细胞癌。

?

适用疾病: Advanced Hepatocellular Carcinoma (HCC)
干预: Particle beam radiation therapy
地点: South Korea
申办方: National Cancer Center, Korea

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06852820 / NCI-2025-06673

68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

AI 简述这是一项II期试验，研究Lu-PSMA-617用于转移性肝细胞癌。

?

适用疾病: Liver Cancer；Hepatocellular Carcinoma；Metastatic Liver Cancer
干预: Lu-PSMA-617
地点: United States
申办方: Melissa Lumish

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06880523

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

AI 简述这是一项II期试验，在加拿大比较STRIDE联合乐伐替尼与STRIDE单药用于不可切除肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: STRIDE (durvalumab + tremelimumab)，Durvalumab，Lenvatinib
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT06911255

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

AI 简述这是一项I/II期试验，研究Tremelimumab+Durvalumab联合TACE用于不可切除肝细胞癌。在韩国开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Unresectable Hepatocellular Carcinoma
干预: Tremelimumab Plus Durvalumab (MEDI4736)，Transarterial chemoembolization (TACE)
地点: South Korea
申办方: Yoon Jun Kim

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06999694

Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

AI 简述这是一项II期试验，在台湾研究质子放疗联合Tremelimumab/Durvalumab用于BCLC B/C期肝细胞癌。

?

适用疾病: HCC - Hepatocellular Carcinoma；Durvalumab；Tremelimumab
干预: Proton radiotherapy，Tremelimumab，Durvalumab
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06999707

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

AI 简述这是一项II期试验，在台湾研究光子放疗联合Tremelimumab/Durvalumab用于BCLC B/C期肝细胞癌。

?

适用疾病: HCC - Hepatocellular Carcinoma；Tremelimumab；Durvalumab
干预: Photon radiotherapy，Tremelimumab，Durvalumab
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07010497

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Irpagratinib联合Atezolizumab和Bevacizumab用于肝细胞癌。

?

适用疾病: Carcinoma, Hepatocellular
干预: irpagratinib
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07018947

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

AI 简述这是一项II期试验，研究阿替利珠单抗联合贝伐珠单抗用于可切除肝癌的围手术期治疗。

?

适用疾病: Resectable Hepatocellular Carcinoma
干预: Atezolizumab and Bevacizumab
地点: Spain
申办方: Fundacion Clinic per a la Recerca Biomédica

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT07042919

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

AI 简述这是一项I/II期试验，研究Zanzalintinib用于晚期肝癌二线及以上治疗，在美国开展。

?

适用疾病: Advanced Hepatocellular Carcinoma；Cirrhosis；Stage III Hepatocellular Carcinoma AJCC v8
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Multigated Acquisition Scan
地点: United States
申办方: Devalingam Mahalingam

正在招募 Phase 4 药物放疗

ClinicalTrials.gov / NCI NCT07059494 / NCI-2025-06198

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

AI 简述这是一项IV期试验，研究阿替利珠单抗和贝伐珠单抗联合Y90放射栓塞用于肝细胞癌肝移植，在美国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Atezolizumab，Bevacizumab，Y^90 Radioembolization
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT07122089

Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

AI 简述这是一项II期试验，在法国研究选择性内放射治疗后联合Tremelimumab和Durvalumab用于不可切除肝细胞癌伴门静脉血栓。

?

适用疾病: Hepatocellular Carcinoma Non-resectable
干预: Selective Internal Radiotherapy，Tremelimumab，Durvalumab
地点: France
申办方: Center Eugene Marquis

正在招募 Phase 4 药物

ClinicalTrials.gov NCT07132515

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

AI 简述这是一项IV期试验，研究抗凝药用于肝硬化伴或不伴肝细胞癌的门静脉血栓患者，在埃及开展。

?

适用疾病: Cirrhosis；HCC - Hepatocellular Carcinoma；Portal Vein Thrombosis
干预: Enoxaparin, warfarrin, or apixaban
地点: Egypt
申办方: Mansoura University

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07174570 / NCI-2025-06192

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

AI 简述这是一项II期试验，研究Celecoxib、Durvalumab、Tremelimumab联合用于晚期或转移性肝癌，在美国开展。

?

适用疾病: Advanced Hepatocellular Carcinoma；Metastatic Hepatocellular Carcinoma；Stage III Hepatocellular Carcinoma AJCC v8
干预: Celecoxib，Durvalumab，Tremelimumab，Biospecimen Collection
地点: United States
申办方: Emory University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07175441 / NCI-2026-03641

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究RBS2418联合Tremelimumab和Durvalumab用于晚期不可切除肝癌，在美国开展。

?

适用疾病: Advanced Unresectable Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: RBS2418，STRIDE (durvalumab + tremelimumab)
地点: United States
申办方: Riboscience, LLC.

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT07219459 / NCI-2026-03870

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

AI 简述这是一项II期试验，研究Visugromab、Nivolumab和Lenvatinib用于晚期肝癌，在美国、德国等地开展。

?

适用疾病: Unresectable or Metastatic Hepatocellular Carcinoma；Child-Pugh A Hepatocellular Carcinoma；Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
干预: Visugromab RDE (recommended dose for expansion)，Nivolumab，Lenvatinib，Placebo Saline Infusion
地点: United States，Germany，Italy，Spain
申办方: CatalYm GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07223424

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

AI 简述这是一项II期试验，研究患者对皮下与静脉注射免疫治疗的偏好。在美国开展。

?

适用疾病: Renal Cell Carcinoma；Non Small Cell Lung Cancer；Melanoma
干预: nivolumab，pembrolizumab
地点: United States
申办方: Diwakar Davar

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT07227012 / NCI-2026-00963

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

AI 简述这是一项I/II期试验，研究PF-08634404联合Ipilimumab用于不可切除肝细胞癌，在美国、日本、波多黎各、台湾等地开展。

?

适用疾病: Carcinoma, Hepatocellular；Hepatocellular Cancer；Hepatocellular Carcinoma
干预: PF-08634404，Ipilimumab
地点: United States，Japan，Puerto Rico，Taiwan
申办方: Pfizer

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT07246668

A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究碳离子放疗联合Atezolizumab和Bevacizumab用于晚期肝细胞癌，在韩国开展。

?

适用疾病: Hepatocellular Carcinoma；Liver Neoplasms；Carcinoma
干预: Carbon Ion Radiotherapy Atezolizumab Bevacizumab
地点: South Korea
申办方: Yonsei University

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT07276100

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

AI 简述这是一项II期试验，研究粪菌移植联合Atezolizumab和Bevacizumab用于一线治疗进展的不可切除肝细胞癌，在意大利开展。

?

适用疾病: Hepato Cellular Carcinoma (HCC)
干预: Fecal microbiota transplantation (FMT)，Atezolizumab & Bevacizumab
地点: Italy
申办方: IRCCS Azienda Ospedaliero-Universitaria di Bologna

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07312292

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

AI 简述这是一项II期试验，研究动脉内血管紧张素II联合钇90放射栓塞用于肝肿瘤。

?

适用疾病: Liver Cancer (Locally Advanced or Metastatic)；Liver Cancer Adult
干预: Angiotensin II (Giapreza®)，Yttrium-90 radioembolization
地点: Netherlands
申办方: Niek Wijnen

正在招募 Phase 4 药物手术/操作

ClinicalTrials.gov / NCI NCT07405086 / NCI-2026-00433

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

AI 简述这是一项IV期试验，研究上午与下午给药免疫治疗用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Hepatocellular Carcinoma
干预: Biospecimen Collection，Immune Checkpoint Inhibitor
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07493668

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

AI 简述这是一项II期试验，比较Fostrox联合Lenvatinib与Lenvatinib用于一线免疫治疗后晚期肝细胞癌，在韩国开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Fostrox，Lenvatinib
地点: South Korea
申办方: CHA University

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07027436

Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

AI 简述这是一项III期试验，比较放疗后Durvalumab和Tremelimumab联合手术与单纯放疗后手术用于可切除肝细胞癌，在加拿大开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Chemotherapy/Radiation
地点: Canada
申办方: Hamilton Health Sciences Corporation

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07461675

Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

AI 简述这是一项III期试验，研究新辅助Atezolizumab治疗对肝细胞癌患者抗肿瘤免疫的影响。

?

适用疾病: Hepato Cellular Carcinoma (HCC)；Immunotherapy
干预: Atezolizumab
地点: Switzerland
申办方: University of Geneva, Switzerland

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05286320

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

AI 简述这是一项I/II期试验，研究Pembrolizumab联合Lenvatinib和SBRT用于伴有门静脉血栓的肝细胞癌。

?

适用疾病: Unresectable Hepatocellular Carcinoma；Pembrolizumab；Lenvatinib
干预: Lenvatinib/Pembrolizumab plus SBRT combinations
地点: Taiwan
申办方: National Taiwan University Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05908916

Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma

AI 简述这是一项II期试验，在韩国研究Atezolizumab联合Bevacizumab及放疗用于晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: AtezoBev with combined radiotherapy
地点: South Korea
申办方: Yonsei University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07151326

Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

AI 简述这是一项II期试验，在台湾研究卡博替尼用于一线免疫联合治疗后进展的肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Cabozantinib
地点: Taiwan
申办方: National Health Research Institutes, Taiwan

即将招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07226063 / NCI-2026-01982

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

AI 简述这是一项II期试验，研究Zanzalintinib联合Durvalumab用于晚期肝细胞癌的维持治疗，在美国开展。

?

适用疾病: Hepatocellular Carcinoma；Liver Cancer；Stage III Hepatocellular Cancer
干预: Durvalumab，Zanzalintinib
地点: United States
申办方: Amit Mahipal

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07495579

Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)

AI 简述这是一项II期试验，比较Lenvatinib与Regorafenib用于免疫治疗后的晚期肝癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Lenvatinib，regorafenib
地点: South Korea
申办方: Asan Medical Center

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07511504

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Y-90放射栓塞联合Durvalumab、Tremelimumab和Zanzalintinib用于不可切除肝细胞癌。

?

适用疾病: Locally Advanced Hepatocellular Carcinoma；Stage III Hepatocellular Carcinoma AJCC v8；Stage IV Hepatocellular Carcinoma AJCC v8
干预: Angiogram，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点: United States
申办方: OHSU Knight Cancer Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07514429

Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial

AI 简述这是一项II期试验，研究Regorafenib用于Lenvatinib治疗失败的不可切除肝细胞癌。在韩国开展。

?

适用疾病: Carcinoma, Hepatocellular；Lenvatinib；Treatment Failure
干预: Regorafenib (BAY 73-4506)
地点: South Korea
申办方: Ju Hyun Shim

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07514455

Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients

AI 简述这是一项II期试验，研究Regorafenib用于一线免疫检查点抑制剂治疗后的晚期肝细胞癌患者。在韩国开展。

?

适用疾病: Carcinoma, Hepatocellular；Hepatic Insufficien；Disease Progression
干预: Regorafenib (BAY 73-4506)
地点: South Korea
申办方: Ju Hyun Shim

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07636785

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

AI 简述这是一项I/II期试验，研究VMD-102用于肝细胞癌和其他实体瘤，在美国开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Metastatic Uveal Melanoma；Renal Cell Carcinoma (RCC)
干预: VMD-102
地点: United States
申办方: VM Discovery, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07689175

Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

AI 简述这是一项II期试验，自适应剂量纳武利尤单抗和伊匹木单抗用于肝细胞癌。在美国等地开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Nivolumab，Ipilimumab (3 mg/kg)
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 1

NCI NCT02675946 / NCI-2018-00241

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

AI 简述这是一项I期试验，研究CGX1321单用或联合Pembrolizumab或Encorafenib+Cetuximab用于晚期实体瘤和晚期胃肠道肿瘤。

?

适用疾病: Stage IIIA Esophageal Cancer；Stage IIIB Esophageal Cancer；Stage IIIC Esophageal Cancer
干预: 未列出
地点: United States
申办方: Curegenix Inc.

正在招募 Phase 1

NCI NCT04429542 / NCI-2020-04796

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

AI 简述这是一项I期试验，研究BCA101单药及联合治疗用于EGFR驱动的晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bicara Therapeutics

正在招募 Phase 1

NCI NCT04518748 / NCI-2020-11570

Y-90 SIRT and SBRT for the Treatment of Unresectable Liver Cancer

AI 简述这是一项I期试验，研究Y-90 SIRT联合SBRT用于不可切除肝癌。

?

适用疾病: Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer；Metastatic Hepatocellular Carcinoma
干预: 未列出
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1

NCI NCT04902443 / NCI-2021-01289

Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV

AI 简述这是一项I期试验，研究Pomalidomide联合Nivolumab用于病毒相关恶性肿瘤，包括头颈癌、鼻咽癌。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: NCI - Center for Cancer Research

正在招募 Phase 1

NCI NCT05274048 / NCI-2022-05652

Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer

AI 简述这是一项I期试验，研究Neratinib联合Fam-Trastuzumab Deruxtecan用于晚期胃食管癌。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1

NCI NCT05848739 / NCI-2023-08892

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

AI 简述这是一项1-2期试验，研究ST316用于晚期不可切除和转移性实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Sapience Therapeutics

正在招募 Phase 1

NCI NCT06108050 / NCI-2024-01130

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究JZP898单药或联合Pembrolizumab用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 1

NCI NCT06384352 / NCI-2024-07039

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究YL211用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06906900 / NCI-2025-02319

Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis

AI 简述这是一项I期试验，研究肿瘤电场治疗用于难治性脊柱转移瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IVB Hepatocellular Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募阶段未标明

NCI NCT07118202 / NCI-2025-05613

TheraBionic Amplitude-Modulated Radiofrequency Therapy for the Treatment of Recurrent Advanced Hepatocellular Carcinoma

AI 简述这是一项试验，研究TheraBionic调幅射频治疗用于复发性晚期肝细胞癌，在美国开展。

?

适用疾病: Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer；Advanced Hepatocellular Carcinoma
干预: 未列出
地点: United States
申办方: Wayne State University/Karmanos Cancer Institute

正在招募 Phase 1

NCI NCT04906434 / NCI-2025-05680

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

AI 简述这是一项I期试验，研究ABSK-011用于晚期实体瘤，在美国开展。

?

适用疾病: BCLC Stage B Hepatocellular Cancer；BCLC Stage C Hepatocellular Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Abbisko Therapeutics Co, Ltd

正在招募 Phase 1

NCI NCT07586046 / NCI-2025-07112

Yttrium-90 Radiation Segmentectomy for the Treatment of Liver Tumors, MARGIN Trial

AI 简述这是一项I期试验，在美国开展，研究Yttrium-90放射节段切除术用于肝肿瘤（包括肝细胞癌、胆管癌和肝转移瘤）。

?

适用疾病: Hepatocellular Carcinoma；Cholangiocarcinoma；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: Northwestern University

正在招募 Phase 1

NCI NCT07197671 / NCI-2025-08356

Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer

AI 简述这是一项I期试验，研究Y-NM600联合免疫检查点抑制剂用于转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT07317505 / NCI-2026-01129

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究JMT108用于治疗晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Conjupro Bio-Pharmaceuticals Inc

正在招募阶段未标明

NCI NCT07223307 / NCI-2026-03472

Single Session MRI Guided Adaptive Stereotactic Ablative Radiotherapy for the Treatment of Liver Cancer, REGULUS Trial

AI 简述这是一项试验，研究MRI引导适应性立体定向消融放疗治疗肝癌。在美国开展。

?

适用疾病: Hepatocellular Carcinoma；Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: Stanford Cancer Institute Palo Alto

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT04221893 / NCI-2019-08355

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

AI 简述这是一项试验，研究放射治疗用于转移性胃肠癌，包括食管癌、胃癌等。

?

适用疾病: Stage IV Esophageal Adenocarcinoma；Stage IV Esophageal Squamous Cell Carcinoma；Stage IV Gastric Cancer
干预: Radiation Therapy (RT)
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04248569

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究DNAJB1-PRKACA多肽疫苗联合纳武利尤单抗和伊匹木单抗用于纤维板层肝细胞癌。

?

适用疾病: Fibrolamellar Hepatocellular Carcinoma (FLC)
干预: DNAJB1-PRKACA peptide vaccine，Nivolumab，Ipilimumab
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 生物制剂联合产品

ClinicalTrials.gov / NCI NCT04282044 / NCI-2021-03252

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究CRX100单药或联合帕博利珠单抗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Triple Negative Breast Cancer；Colorectal Cancer
干预: CRX100 suspension for infusion，Fludarabine，Cyclophosphamide
地点: United States
申办方: BioEclipse Therapeutics

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04499833

HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma

AI 简述这是一项HepatoPredict预后工具用于肝细胞癌肝移植决策的试验。在葡萄牙开展。

?

适用疾病: Hepatocellular Carcinoma, Scirrhous；Recurrence Tumor
干预: liver transplant
地点: Portugal
申办方: Centro Hospitalar de Lisboa Central

正在招募 Phase 1 联合产品

ClinicalTrials.gov NCT04587739

Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.

AI 简述这是一项I期试验，研究术前立体定向体部放疗用于肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Surgery with Neoadjuvant stereotactic body radiation therapy
地点: France
申办方: University Hospital, Lille

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04745390

Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer

AI 简述这是一项试验，比较标准剂量与放射生物学引导剂量选择的SBRT用于肝癌或肝转移。在加拿大开展。

?

适用疾病: Hepatocellular Carcinoma；Liver Metastases
干预: Radiation therapy
地点: Canada
申办方: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04745403

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

AI 简述这是一项1期试验，研究mRNA HBV/TCR T细胞用于HBV相关肝细胞癌。在新加坡开展。

?

适用疾病: Hepatocellular Carcinoma
干预: mRNA HBV/TCR T-cells
地点: Singapore
申办方: Lion TCR Pte. Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04823403

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究肝动脉注射Ipilimumab联合静脉Nivolumab用于晚期肝癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Nivolumab，Ipilimumab
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募阶段未标明手术/操作放疗

ClinicalTrials.gov NCT04996914

Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma

AI 简述这是一项试验，研究TACE后辅助立体定向放疗用于不可切除肝细胞癌，在德国开展。

?

适用疾病: Hepatocellular Carcinoma Non-resectable
干预: TACE，SBRT
地点: Germany
申办方: RWTH Aachen University

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05003895 / NCI-2021-09114

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

AI 简述这是一项I期试验，研究GPC3靶向CAR-T细胞用于晚期GPC3表达实体瘤。

?

适用疾病: Hepatocellular Carcinoma；Hepatocellular Cancer；Metastatic Hepatocellular Carcinoma
干预: Cyclophosphamide，CAR-T cell，Fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05092373 / NCI-2021-11360

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

AI 简述这是一项I期试验，研究肿瘤电场治疗联合卡博替尼或Pembrolizumab+白蛋白紫杉醇用于腹部/胸部晚期实体瘤。

?

适用疾病: Advanced Breast Carcinoma；Advanced Endometrial Carcinoma；Advanced Fallopian Tube Carcinoma
干预: Atezolizumab，Cabozantinib S-malate，Nab-paclitaxel，Tumor Treating Fields Therapy
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT05096715 / NCI-2022-01622

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

AI 简述这是一项I期试验，研究Atezolizumab联合贝伐珠单抗及SBRT用于不可切除肝细胞癌。

?

适用疾病: Unresectable Hepatocellular Carcinoma；Unresectable Hepatocellular Cancer
干预: Atezolizumab，Bevacizumab，Stereotactic body radiation therapy (SBRT)
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05176483 / NCI-2022-05617

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

AI 简述这是一项I期试验，研究Zanzalintinib联合免疫药物用于实体瘤，在多国开展。

?

适用疾病: Renal Cell Carcinoma (RCC)；Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Urothelial Carcinoma (UC)
干预: Zanzalintinib，Nivolumab，Ipilimumab，Nivolumab + Relatlimab
地点: United States，Australia，Austria，Belgium 等 9 个
申办方: Exelixis

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05203120

A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究质子疗法用于肝细胞癌，在丹麦开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Proton therapy
地点: Denmark
申办方: University of Aarhus

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05488522

SBRT With Atezo/Bev for HCC

AI 简述这是一项I期试验，研究立体定向放疗联合Atezo/Bev用于肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: SBRT + atezolizumab and bevacizumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项1期试验，研究Enzelkitug单药或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；NSCLC；HNSCC
干预: Enzelkitug，Atezolizumab，Pembrolizumab
地点: United States，Australia，Belgium，Canada 等 6 个
申办方: Genentech, Inc.

正在招募 Phase 1 器械药物

ClinicalTrials.gov NCT05701488

SIRT With Tremelimumab and Durvalumab for Resectable HCC

AI 简述这是一项I期试验，在美国研究SIRT联合Durvalumab和Tremelimumab用于可切除肝癌。

?

适用疾病: Resectable Hepatocellular Carcinoma；Hepatocellular Carcinoma；Hepatocellular Cancer
干预: Durvalumab，Tremelimumab，SIRT
地点: United States
申办方: Jiping Wang, MD, PhD

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT05727787 / NCI-2023-05315

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

AI 简述这是一项I期试验，研究立体定向体部放疗用于不可切除或转移性肝细胞癌。

?

适用疾病: Liver Cancer；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: Stereotactic Body Radiation Treatment
地点: United States
申办方: University of Kansas Medical Center

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05791448 / NCI-2023-01399

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

AI 简述这是一项I期试验，研究AU409用于晚期原发性肝癌或伴肝转移的实体瘤。

?

适用疾病: Advanced Cholangiocarcinoma；Advanced Hepatocellular Carcinoma；Advanced Malignant Solid Neoplasm
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，RNA Transcription Modulator AU-409
地点: United States
申办方: University of Southern California

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05937295

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

AI 简述这是一项I期试验，研究融合转录本肽疫苗Fusion-VAC-XS15用于纤维板层肝细胞癌，在德国开展。

?

适用疾病: Fibrolamellar Hepatocellular Carcinoma
干预: Fusion-VAC-XS15
地点: Germany
申办方: University Hospital Tuebingen

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06005740

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

AI 简述这是一项I期试验，研究TORL-4-500用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumor；Hepatocellular Carcinoma
干预: TORL-4-500
地点: United States，Canada
申办方: TORL Biotherapeutics, LLC

正在招募 Phase 1 器械药物

ClinicalTrials.gov NCT06044506

Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究自体自然杀伤细胞疗法用于肝细胞癌。在印度尼西亚开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Autologous Natural Killer Cell Therapy，Clinimacs Plus
地点: Indonesia
申办方: Dr Cipto Mangunkusumo General Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06066138

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

AI 简述这是一项I期试验，研究基于治疗药物监测的Atezolizumab给药方案用于多种晚期肉瘤和肺癌。在美国开展。

?

适用疾病: Locally Advanced Alveolar Soft Part Sarcoma；Metastatic Alveolar Soft Part Sarcoma；Locally Advanced Non Small Cell Lung Cancer
干预: Atezolizumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 基因治疗

ClinicalTrials.gov NCT06198296

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

AI 简述这是一项I期试验，研究IL-15和IL-21武装的GPC3-CAR T细胞用于GPC3阳性实体瘤。

?

适用疾病: Hepatoblastoma；Hepatocellular Carcinoma；Wilms Tumor
干预: 21.15.GPC3-CAR T cells
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06326502

A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究多靶点酪氨酸激酶抑制剂ETN101用于晚期肝细胞癌，在韩国开展。

?

适用疾病: Hepatocellular Carcinoma；Advanced Hepatocellular Carcinoma；Liver Cancer
干预: ETN101
地点: South Korea
申办方: Etnova Therapeutics Corp.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06478693

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

AI 简述这是一项I期试验，研究MT-303单用或联合用于GPC3阳性晚期肝癌，在澳韩台开展。

?

适用疾病: Hepatocellular Carcinoma
干预: MT-303，MT-303 +Atezolizumab + Bevacizumab
地点: Australia，South Korea，Taiwan
申办方: Myeloid Therapeutics

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06582017 / NCI-2024-07730

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

AI 简述这是一项I期试验，研究QXL138AM用于实体瘤和多发性骨髓瘤。在美国开展。

?

适用疾病: Ovarian Cancer；Pancreas Cancer；Urothelial Carcinoma
干预: QXL138AM Injection every 2 weeks by IV Infusion
地点: United States
申办方: Nammi Therapeutics Inc

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06595108

Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma

AI 简述这是一项试验，研究Atezolizumab和贝伐珠单抗联合立体定向放疗用于晚期肝细胞癌，在韩国开展。

?

适用疾病: Advanced Hepatocellular Carcinoma；Chemotherapy；Stereotactic Body Radiotherapy
干预: Stereotactic body radiotherapy
地点: South Korea
申办方: Yonsei University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06600321 / NCI-2024-08329

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究ALN-BCAT用于晚期肝细胞癌，在美国、意大利、韩国等地开展。

?

适用疾病: Advanced Hepatocellular Carcinoma；Metastatic Hepatocellular Carcinoma；Stage III Hepatocellular Cancer
干预: ALN-BCAT，Pembrolizumab
地点: United States，Italy，South Korea
申办方: Alnylam Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06636435

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

AI 简述这是一项I期试验，研究CBA-1205用于晚期实体瘤、肝癌、黑色素瘤和儿童癌症，在日本开展。

?

适用疾病: Solid Tumors；Hepatocellular Carcinoma (HCC)；Malignant Melanoma
干预: CBA-1205 Part 1，CBA-1205 Part 2，CBA-1205 Part 3，CBA-1205 Part 4
地点: Japan
申办方: Chiome Bioscience Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06687941

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

AI 简述这是一项I期试验，研究AST-201用于GPC3阳性晚期实体瘤，在韩国开展。

?

适用疾病: Neoplasms；Carcinoma, Hepatocellular；Carcinoma, Non-Small-Cell Lung
干预: AST-201
地点: South Korea
申办方: Aptamer Sciences, Inc.

正在招募 Phase 1 器械药物

ClinicalTrials.gov / NCI NCT06710223 / NCI-2025-00370

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

AI 简述这是一项I期试验，研究冷冻消融联合SD-101动脉输注及Durvalumab和Tremelimumab用于肝癌。在美国开展。

?

适用疾病: Hepatocellular Carcinoma；Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer
干预: SD-101，Cryotherapy，Tremelimumab，Durvalumab
地点: United States
申办方: University of California, San Diego

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06789198

Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA

AI 简述这是一项I期试验，研究肽疫苗Fusion-VAC-XS15用于纤维板层肝细胞癌。

?

适用疾病: Fibrolamellar Hepatocellular Carcinoma (FLC)
干预: Vaccination of Fusion-VAC-XS15
地点: Germany
申办方: University Hospital Tuebingen

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06883539

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

AI 简述这是一项I期试验，研究LXP1788用于晚期实体瘤。

?

适用疾病: Solid Tumor Malignancies, Cancer；Solid Cancers；Solid Tumor Cancer
干预: LXP1788 is administered intravenously via Port-A
地点: Taiwan
申办方: LaunXP Biomedical Co., Ltd.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06914648

The Dragon PLC Trial (DRAGON-PLC)

AI 简述这是一项试验，研究门静脉栓塞联合肝静脉栓塞用于原发性肝癌。

?

适用疾病: Primary Liver Cancer；Hepatocellular Carcinoma (HCC)；Cholangiocarcinoma
干预: Portal Vein Embolization，Hepatic Vein Embolization
地点: United States，Australia，Austria，Belgium 等 8 个
申办方: Maastricht University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06915753 / NCI-2025-03305

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

AI 简述这是一项I期试验，研究TYRA-430用于FGFR异常的肝细胞癌和实体瘤。

?

适用疾病: Metastatic Hepatocellular Carcinoma；Solid Tumors；Solid Tumor, Adult
干预: TYRA-430
地点: United States，Canada，South Korea，Taiwan
申办方: Tyra Biosciences, Inc

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT07075120 / NCI-2026-03248

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

AI 简述这是一项I期试验，研究Ipilimumab和Nivolumab联合SBRT用于局部晚期肝细胞癌，在美国开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Stage III Hepatocellular Cancer；Locally Advanced Hepatocellular Carcinoma
干预: Ipilimumab and Nivolumab，Stereotactic Body Radiotherapy (SBRT)
地点: United States
申办方: University of Hawaii

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07148050 / NCI-2026-01281

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

AI 简述这是一项I期试验，在美国研究GPC3靶向CAR-T细胞用于儿童实体瘤。

?

适用疾病: Solid Tumor (Excluding CNS)；Liver Cell Carcinoma；Malignant Rhabdoid Tumor
干预: SC-CAR.GPC3xIL15.21 CAR T cells
地点: United States
申办方: Seattle Children's Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07164313 / NCI-2025-09247

A Study of ZW251 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ZW251用于晚期实体瘤，在美国、爱尔兰、日本、葡萄牙等地开展。

?

适用疾病: Hepatocellular Carcinoma；Squamous Cell Non-Small Cell Lung Cancer；Germ Cell Tumor
干预: ZW251
地点: United States，Ireland，Japan，Portugal 等 2 个
申办方: Zymeworks BC Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07197554

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

AI 简述这是一项I/IB期试验，研究ST-01156用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumors；Ewing Sarcoma；Hepatocellular Carcinoma (HCC)
干预: ST-01156
地点: United States
申办方: SEED Therapeutics, Inc.

正在招募阶段未标明放疗

ClinicalTrials.gov NCT07252323

A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)

AI 简述这是一项单臂II期试验，研究碳离子放疗用于既往接受过经动脉放射栓塞治疗的肝细胞癌，于韩国开展。

?

适用疾病: Carcinoma；Hepatocellular Carcinoma
干预: Carbon Ion Radiotherapy
地点: South Korea
申办方: Yonsei University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07369505

Sapu003 in Advanced mTOR-sensitive Solid Tumors

AI 简述这是一项I期试验，研究Sapu003用于晚期mTOR敏感实体瘤，在澳大利亚开展。

?

适用疾病: Breast Cancer Metastatic；Renal Cell Carcinoma (RCC)；Neuroendocrine Tumors
干预: Sapu003，Exemestane 25 MG
地点: Australia
申办方: SAPU NANO (US) LLC

正在招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT07408804

Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

AI 简述这是一项试验，比较TACE联合仑伐替尼与仑伐替尼单药用于不可切除肝细胞癌，在孟加拉国开展。

?

适用疾病: Unresectable Hepatocellular Carcinoma (HCC)
干预: TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib)，Lenvatinib
地点: Bangladesh
申办方: Bangladesh Medical University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07419841

A Phase 1 Study of the Safety and Tolerability of CTX-10726

AI 简述这是一项I期试验，在美国开展，研究CTX-10726用于多种晚期实体瘤。

?

适用疾病: Gastroesophageal Cancer (GC)；Hepatocellular Carcinoma (HCC)；Endometrial Cancer
干预: CTX-10726
地点: United States
申办方: Compass Therapeutics

正在招募阶段未标明放疗

ClinicalTrials.gov NCT07628751

A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC

AI 简述这是一项标准治疗对比立体定向消融放疗用于早期肝细胞癌的试验，在澳大利亚、加拿大开展。

?

适用疾病: Early Hepatocellular Carcinoma
干预: Stereotactic Ablative Body Radiotherapy (SABR)，Therapies
地点: Australia，Canada
申办方: University Health Network, Toronto

正在招募阶段未标明药物

ClinicalTrials.gov NCT07657897

The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection

AI 简述这是一项非分期试验，研究麻醉对肝细胞癌切除中炎症和NETosis的影响，在罗马尼亚开展。

?

适用疾病: Hepato Cellular Carcinoma (HCC)；Sedation and Analgesia；Ablation Techniques
干预: Sedation using combination of Propofol and Fentanyl.，Sedation using combination of Propofol and Fentanyl and lidocaine
地点: Romania
申办方: Iuliu Hatieganu University of Medicine and Pharmacy

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07489976

IIT2025-03-YANG-LIFT-HCC

AI 简述这是一项II期试验，在美国开展，研究STRIDE方案联合局部治疗用于肝细胞癌。

?

适用疾病: Hepato Cellular Carcinoma
干预: STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)
地点: United States
申办方: Ju Dong Yang

即将招募 Phase 3 生物制剂药物

ClinicalTrials.gov NCT06680258

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

AI 简述一项III期试验，TPST-1120联合Atezolizumab和Bevacizumab用于未接受系统治疗的不可切除或转移性HCC。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: TPST-1120，Atezolizumab，Bevacizumab
地点: 未列出
申办方: Tempest Therapeutics

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07620574

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

AI 简述这是一项III期长期扩展试验，用于既往参加过Exelixis研究的癌症患者，包括肾癌、胰腺神经内分泌肿瘤、肝细胞癌等。

?

适用疾病: Cancer；Renal Cell Carcinoma (RCC)；Pancreatic Neuroendocrine Tumors (pNET)
干预: Cabozantinib，Zanzalintinib，Atezolizumab，Nivolumab
地点: 未列出
申办方: Exelixis

暂时不招募阶段未标明

NCI NCT04152343 / NCI-2020-07561

An Intraoperative Guidance Platform for Patients Undergoing Radio Frequency Ablation for Liver Cancer

AI 简述这是一项平台研究，用于肝癌患者接受射频消融时的术中指导。

?

适用疾病: Hepatocellular Carcinoma
干预: 未列出
地点: United States
申办方: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

暂时不招募 O

NCI NCT06204159 / NCI-2024-01059

End hole or Pressure-Modulated Delivery Catheter for Treatment in Patients with Liver Cancer and Neuroendocrine Tumor with Liver Metastases

AI 简述这是一项其他类型试验，比较两种导管用于肝癌和神经内分泌肿瘤肝转移。

?

适用疾病: Hepatocellular Carcinoma；Neuroendocrine Tumor；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

暂时不招募 Phase 1

NCI NCT06968195 / NCI-2025-03008

Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究靶向GPC3的CAR-T细胞(RPCAR01)用于晚期肝细胞癌。

?

适用疾病: Stage III Hepatocellular Cancer；Stage IV Hepatocellular Cancer；Metastatic Hepatocellular Carcinoma
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT05971628

Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma

AI 简述这是一项试验，研究切除和部分肝移植联合延迟肝切除用于肝细胞癌，在法国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: RAPID procedure
地点: France
申办方: Assistance Publique - Hôpitaux de Paris

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06060847

Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)

AI 简述这是一项试验，比较肝切除联合袖状胃切除术与单独肝切除术用于代谢综合征相关肝细胞癌。

?

适用疾病: Carcinoma, Hepatocellular；Metabolic Syndrome
干预: Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome，Liver resection for HCC induced by metabolic syndrome
地点: Italy
申办方: Ospedale V. Fazzi

即将招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT06836778

Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices

AI 简述这是一项试验，比较卡维地洛单药与联合内镜静脉曲张结扎术用于肝癌伴高危食管静脉曲张的首次出血预防，在印度开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Carvedilol Tablets，Endoscopic Variceal Ligation
地点: India
申办方: Institute of Liver and Biliary Sciences, India

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07224568

Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors

AI 简述这是一项I期试验，研究GPC3靶向CAR-T细胞（SC-CAR.GPC3xIL15.21）用于多种实体瘤。

?

适用疾病: Solid Tumor (Excluding CNS)；Hepatocellular Carcinoma；Liver Cell Carcinoma
干预: SC-CAR.GPC3xIL15.21 CAR T cells
地点: United States
申办方: Seattle Children's Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07365839

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究西米普利单抗联合或不联合菲安利单抗用于Y90放射栓塞后的肝细胞癌。在美国开展。

?

适用疾病: Hepatocellular Carcinoma
干预: Arm 1 cemiplimab，Arm 2 cemiplimab and fianlimab
地点: United States
申办方: Virginia Commonwealth University

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07430202

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

AI 简述这是一项I期试验，在美国研究DNAJB1-PRKACA肽疫苗联合DRP-104、Nivolumab和Ipilimumab用于晚期纤维板层肝癌。

?

适用疾病: Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
干预: DNAJB1-PRKACA Peptide Vaccine，DRP-104，Nivolumab，Ipilimumab
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07446257

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

AI 简述这是一项早期I期试验，研究ateganosine联合Cadonilimab用于可切除肝细胞癌。

?

适用疾病: Resectable Hepatocellular Carcinoma
干预: ateganosine，Cadonilimab
地点: United States
申办方: University of Texas Southwestern Medical Center

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07627191

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

AI 简述这是一项早期I期试验，研究GLP-1受体激动剂（司美格鲁肽）联合标准治疗用于一线转移性胰腺癌、结直肠癌或肝细胞癌。

?

适用疾病: Pancreatic Cancer；Colorectal Cancer；Hepatocellular Carcinoma
干预: GLP1-RA (semaglutide)
地点: United States
申办方: University of Arizona

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07690683

Patients With Hepatocellular Carcinoma (HCC)

AI 简述这是一项试验，研究粪菌移植用于肝细胞癌。在意大利等地开展。

?

适用疾病: Hepatocellular Carcinoma；Hepatocellular Cancer；Liver Diseases
干预: Fecal microbiota transplantation performed via colonoscopy.，Simulated Colonoscopy With Placebo Capsules in Addition to Standard Treatment
地点: Italy
申办方: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT05195294

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

AI 简述这是一项II期试验，研究HBV-TCR T细胞（LioCyx-M）单药或联合仑伐替尼用于HBV相关肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma；Liver Cancer, Adult；Liver Cell Carcinoma
干预: LioCyx-M，Lenvatinib
地点: 未列出
申办方: Lion TCR Pte. Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05897138

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

AI 简述这是一项II期试验，研究Lenvatinib联合Tislelizumab用于晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06069947

SALT for Liver Cirrhosis With HCC

AI 简述这是一项试验，研究序贯成人左外叶肝移植用于肝硬化伴肝细胞癌。

?

适用疾病: HCC；Liver Cirrhosis
干预: sequential adult left lateral lobe liver transplantation (SALT)
地点: 未列出
申办方: RenJi Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06253598

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究瘤内注射重组人腺病毒5型联合Tislelizumab和Lenvatinib用于晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Recombinant Human Adenovirus Type 5，Lenvatinib，Tislelizumab
地点: 未列出
申办方: The First Affiliated Hospital of Bengbu Medical University

即将招募 Phase 4 药物手术/操作

ClinicalTrials.gov NCT06311916

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

AI 简述这是一项IV期试验，研究HAIC联合替雷利珠单抗和仑伐替尼新辅助治疗用于可切除肝细胞癌。

?

适用疾病: HCC
干预: HAIC + Tirelizumab +lenvatinib +liver resection，liver resection
地点: 未列出
申办方: Chen Xiaoping

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06375317

HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

AI 简述这是一项II期试验，研究HAIC联合PD-L1抑制剂加瑞戈非尼用于免疫治疗失败的晚期肝细胞癌。

?

适用疾病: HCC - Hepatocellular Carcinoma
干预: PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets
地点: 未列出
申办方: Yehua Shen

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06400160

Clinical Trial of TB511 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究TB511联合Keytruda用于晚期实体瘤，包括非小细胞肺癌、前列腺癌等。

?

适用疾病: NSCLC；Prostate Cancer；Colorectal Cancer
干预: TB511，Keytruda
地点: 未列出
申办方: Twinpig Biolab, Inc.

即将招募 Phase 4 药物手术/操作

ClinicalTrials.gov NCT06496815

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

AI 简述这是一项4期试验，研究多纳非尼联合免疫和局部治疗用于不可切除肝细胞癌。

?

适用疾病: Unresectable Hepatocellular Carcinoma
干预: Donafenib，transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy，PD-1,PD-L1
地点: 未列出
申办方: Tongji Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06535737

A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

AI 简述一项II期试验，研究Cabozantinib用于既往接受过Atezolizumab和Bevacizumab的肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma Non-resectable
干预: Cabozantinib
地点: 未列出
申办方: Chulalongkorn University

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT06538935

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究SBRT联合阿德贝利单抗和阿帕替尼用于肝细胞癌围手术期和转化治疗。

?

适用疾病: Hepatocellular Carcinoma；SBRT；Immune Checkpoint Blockade
干预: adbelimumab，SBRT，apatinib
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 生物制剂

ClinicalTrials.gov NCT06563947

Single Arm Clinical Trial (Gut Microbiota and HCC)

AI 简述这是一项II期试验，研究口服肠菌胶囊用于肝癌。

?

适用疾病: Liver Cancer
干预: Oral enterobacterium capsules
地点: 未列出
申办方: Xu Yong, MD

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06584071

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

AI 简述这是一项I/II期试验，研究PM8002联合PM1009用于一线肝细胞癌。

?

适用疾病: HCC；Liver Cancer
干预: PM8002，PM1009，atezolizumab，bevacizumab
地点: 未列出
申办方: Biotheus Inc.

即将招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT06645314

Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma

AI 简述这是一项早期I期试验，研究BST06注射液用于晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: Group A，Group B
地点: 未列出
申办方: BioSyngen Pte Ltd

即将招募 Phase 4 药物其他

ClinicalTrials.gov NCT06923176

Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment

AI 简述这是一项IV期试验，研究鳖甲软肝片用于肝癌根治术后。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Biejia-Ruangan compound，Routine medical care
地点: 未列出
申办方: Zhiyun Yang

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06958484

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

AI 简述这是一项II期试验，研究QL1706联合贝伐珠单抗用于高复发风险肝细胞癌术后辅助治疗。

?

适用疾病: HCC - Hepatocellular Carcinoma；Adjuvant Treatment
干预: Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
地点: 未列出
申办方: The Affiliated Hospital of Xuzhou Medical University

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT06984718

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

AI 简述这是一项II期试验，比较AK104联合Lenvatinib与Lenvatinib用于肝癌二线治疗。

?

适用疾病: HCC；Hepatocellular Carcinoma
干预: AK104+lenvatinib，lenvatinib
地点: 未列出
申办方: Akeso

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06994572

Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma

AI 简述这是一项I期试验，研究CT-01单药或联合依维莫司用于中晚期肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: CT-01，EVEROLIMUS
地点: 未列出
申办方: Captor Therapeutics S.A.

即将招募阶段未标明药物

ClinicalTrials.gov NCT07077798

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

AI 简述这是一项试验，研究信迪利单抗联合仑伐替尼用于VETC特征肝细胞癌肝切除术后辅助治疗。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Sintilimab，Lenvatinib
地点: 未列出
申办方: Wan-Guang Zhang

即将招募阶段未标明药物

ClinicalTrials.gov NCT07115550

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究Iparomlimab和Tuvonralimab注射液联合Regorafenib用于晚期二线及以上肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)
干预: Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib
地点: 未列出
申办方: Huai'an First People's Hospital

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07128251

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

AI 简述这是一项II期试验，研究TACE联合Iparomlimab、Tuvonralimab和贝伐珠单抗用于不可切除非转移性肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Immunotherapy；PD-1
干预: TACE treatment，Iparomlimab and Tuvonralimab Injection (QL1706)，Bevacizumab
地点: 未列出
申办方: Anhui Provincial Hospital

即将招募 Phase 4 药物

ClinicalTrials.gov NCT07160361

Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB

AI 简述这是一项IV期试验，研究Lenvatinib联合Losartan用于乙肝表面抗原阳性肝癌患者的术后辅助治疗。

?

适用疾病: Carcinoma, Hepatocellular
干预: Lenvatinib + losartan
地点: 未列出
申办方: Second Affiliated Hospital of Xi'an Jiaotong University

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07168668

Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment

AI 简述这是一项II期试验，研究部分免疫增强TACE联合度伐利尤单抗和曲美木单抗用于不可切除肝癌。

?

适用疾病: HCC；Tace；Immunotherapy
干预: Transarterial chemoembolization，durvalumab and tremelimumab
地点: 未列出
申办方: Chang Gung Memorial Hospital

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07179900

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

AI 简述这是一项II期试验，研究放疗联合QL1706和贝伐珠单抗用于不可切除非转移性肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: QL1706，Radiotherapy，Sintilimab，Bevacizumab
地点: 未列出
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07252661

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ACC-1898用于晚期实体瘤。

?

适用疾病: Hepatocellular Carcinoma；Renal Cell Carcinoma；Thyroid Carcinoma, Medullary
干预: ACC-1898
地点: 未列出
申办方: AccSalus Biosciences, Inc.

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07282509

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

AI 简述这是一项I/II期试验，研究紫杉醇脂质体动脉灌注联合全身治疗（HA131、Enlonstobart、派姆单抗、仑伐替尼）二线治疗晚期肝细胞癌。

?

适用疾病: Advanced Hepatocellular Carcinoma (HCC)
干预: HA131，Enlonstobart Injection，Pembrolizumab Injection，Lenvatinib Mesilate Capsules
地点: 未列出
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07297654

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

AI 简述这是一项II期试验，研究仑伐替尼一线用于Child-Pugh B级不适合根治性治疗的肝细胞癌。

?

适用疾病: Advanced Hepatocellular Carcinoma
干预: Lenvatinib
地点: 未列出
申办方: National Cancer Center, Korea

即将招募 Phase 1, Phase 2 器械药物

ClinicalTrials.gov NCT07522411

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

AI 简述这是一项I/II期试验，研究FOLFOX-HAIC-TACE联合信迪利单抗和贝伐珠单抗新辅助治疗用于可切除的高复发风险肝细胞癌。

?

适用疾病: Hepatocellular Carcinoma
干预: FOLFOX regimen，Immunotherapy，targeted therapy，cTACE
地点: 未列出
申办方: BinYong Liang

即将招募阶段未标明药物

ClinicalTrials.gov NCT07535840

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

AI 简述这是一项试验，研究Firsekibart、Tislelizumab和Lenvatinib联合用于不可切除的TP53突变肝癌。

?

适用疾病: HCC - Hepatocellular Carcinoma；TP53 Gene Mutation；Unresectable
干预: Firsekibart + Tislelizumab + Lenvatinib
地点: 未列出
申办方: Tongji Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07623369

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究HH160用于晚期实体瘤。

?

适用疾病: Solid Tumor；Non-small Cell Lung Cancer；Hepatocellular Carcinoma
干预: HH160
地点: 未列出
申办方: Huahui Health

即将招募 Phase 4 药物放疗

ClinicalTrials.gov NCT07668570

SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma

AI 简述这是一项IV期试验，研究SBRT联合QL1706作为肝癌二线治疗。

?

适用疾病: HCC - Hepatocellular Carcinoma
干预: Stereotactic Body Radiation Therapy (SBRT)，QL1706
地点: 未列出
申办方: Hebei Medical University Fourth Hospital

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT05750329

Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)

AI 简述这是一项试验，研究肝脏移植联合两阶段肝切除用于不可切除肝癌。

?

适用疾病: Liver Transplant Disorder；Hepatic Cancer；End-stage Liver Disease
干预: assisted liver transplantation combined with two-stage hepatectomy
地点: 未列出
申办方: RenJi Hospital

术语	中文意思	对找临床试验有什么用
肝细胞癌 / HCC	最常见的原发性肝癌类型。	海外试验常用 hepatocellular carcinoma 或 HCC，而不只写 liver cancer。
不可切除 / Unresectable	通常指无法通过手术完整切除，具体由医生评估。	很多系统治疗试验会限定 unresectable HCC。
HBV-related HCC	和乙肝相关的肝细胞癌。	部分试验会关注 HBV 状态、抗病毒治疗或肝功能要求。
BCLC stage	肝癌常用分期体系之一。	试验可能会限定 BCLC B 或 C 等阶段。
Immunotherapy	免疫治疗方向，例如 PD-1、PD-L1、CTLA-4 等。	可以找免疫联合 VEGF/TKI 或二线免疫治疗试验。
Child-Pugh	评估肝功能状态的评分。	很多肝癌试验会要求 Child-Pugh A 等条件。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

肝癌

当前同步到的治疗类试验